NSE/LUPIN

LUPINLupin Ltd

Healthcare · NSE

₹2,326.1-0.04%

52-wk low52-WEEK RANGE52-wk high

₹1,851.8+25.6% from low ·-1.3% from high₹2,357.3

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

LUPIN+47.69% · 1Y

Range high ₹2,402.9Range low ₹504.75Latest ₹2,326.1Powered by TradingView · live NSE data

HealthcareLargecap

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite67/100

Performance

—

Not enough price history to score.

Valuation

Low

Appears to be fairly valued to cheap vs peers.

· P/E 23.0 vs sector median 37.8 — 39% cheaper

Growth

Medium

Steady but not standout growth.

· Revenue YoY +13.5%
· Profit YoY +71.4% — strong earnings growth

Profitability

Medium

Average profitability vs peers.

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeA(77/100)

Durability

79/100

Financially resilient — strong quality + solvency profile.

Show 3 drivers

Piotroski F-score4/8 (50pt)
Altman Z" score3.00 (100pt)
Debt/Equity0.32 (99pt)

Valuation

70/100

Fairly priced — not a bargain, not stretched.

Show 4 drivers

P/E vs sector (23.0 / 37.8)61% (100pt)
P/B5.43 (70pt)
Dividend yield0.52% (13pt)
EV/EBITDA15.5 (40pt)

Momentum

83/100

Strong, confirmed momentum across price + technicals.

Show 4 drivers

DMA-trend alignmentstrong up (100pt)
RSI (14)55.0 (60pt)
Price vs 200-DMA+11.9% (84pt)
MACD regimebullish (75pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)23.02

UNDERVALUED

CheapestP/E 23.0 at 25th %ile of sector — cheaper than 75% of peers.Most expensive

P/B5.43

FAIR

CheapestP/B 5.43 at 46th %ile of sector.Most expensive

EV/EBITDA15.50

FAIR

Monthly seasonality

Avg monthly return over 10 years · historical — not a forecast

Best: Apr +8.44% · Worst: Feb -5.19%

Jan

-0.0%

50% win

Feb

-5.2%

40% win

Mar

-2.0%

40% win

Apr

+8.4%

80% win

May

-3.7%

30% win

Jun

+2.6%

Monthly return distribution

Distribution of 120 monthly returns

Mean

+0.68%

Median

+0.18%

Std dev

8.77%

Best

+41.7%

Worst

-20.5%

% positive

53%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 1

Bankruptcy risk low (Altman Z″ 3.00)
Z″ above 2.60 sits squarely in the 'safe' zone

WEAKNESSES · 0

No material weaknesses flag from the numbers

OPPORTUNITIES · 1

Strong uptrend — DMA stack bullish
Price > 20-DMA > 50-DMA > 200-DMA: momentum tailwind intact

THREATS · 0

No immediate threats from the data

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

-0.0%

-0.3%

+0.5%

+6.2%

+17.4%

+17.3%

+51.4%

+17.3%

10Y

+4.0%

Fundamentals

VALUATION

Market cap

₹1,06,756 Cr

P/E (TTM)

23.0

P/E (fwd)

—

next 12m

P/B

5.43

EV/EBITDA

15.5

Book value

—

per share

PROFITABILITY · QUALITY

ROE

—

ROCE

—

Net margin

14.4%

Op margin

—

Gross margin

—

D/E

0.32

GROWTH · MARKET

Rev YoY

+13.5%

Profit YoY

+71.4%

Div yield

0.52%

Payout

—

52w change

—

Beta

—

Pros and cons

Auto-derived from ratios · not a buy/sell recommendation

PROS · 2

+Trading at -39.2% vs sector median P/EP/E 23.0 vs Healthcare median 37.8 — relative value on earnings
+Profit growing fast (+71.4% YoY)Operating leverage kicking in — bottom line out-growing top line

CONS · 0

No material concerns surface from the ratios alone — still layer qualitative research.

Sector-relative context

Healthcare · 24 peers

P/E (TTM)

This stock

23.02

Sector median

37.85

Rank 6/24 (79th %ile)

ROE

This stock

—

Sector median

13.8%

—

P/B

This stock

5.43

Sector median

5.81

Rank 11/24 (58th %ile)

Quality score · Piotroski F-score

4 / 8

Mixed quality — several weak points

✗Profitable (positive net income)· Most basic check — company makes money
✗Positive return on assets· Assets generate returns
✓Positive operating cash flow· Profits are backed by real cash, not accruals
✓Operating CF exceeds net profit· Healthy cash conversion — no aggressive revenue recognition
✓Long-term debt decreased YoY· Deleveraging — lower refinancing risk
✗ROA improved YoY· Getting more productive with the asset base
✗Operating margin expanded YoY· Pricing power or cost discipline
✓Asset turnover improved YoY

Forensic score · Altman Z″ (emerging markets)

Bankruptcy-risk predictor · 1995 Altman emerging-market revision

SAFE3.00

Z″ = 3.00 — well inside the SAFE zone. Low bankruptcy risk signal across liquidity, profitability and solvency inputs.

Component	Ratio	Weight	Contribution
Working Capital / Total Assets (A)	0.100	×6.56	0.656
Retained Earnings / Total Assets (B)	0.426	×3.26	1.388
EBIT / Total Assets (C)	0.025	×6.72	0.170
Book Equity / Total Liabilities (D)	0.754	×1.05	0.792

Zones: Z″ ≥ 2.60 safe · 1.10–2.60 grey · < 1.10 distress. Working capital proxied from reported cash + 10% buffer (exact 'current assets − current liabilities' line not ingested). Treat as directional.

Quarterly results

Last 5 quarters · ₹ Cr (Screener.in-grade depth)

Metric	2024-Q3	2024-Q4	2025-Q1	2025-Q2	2025-Q4
Revenue	5,497	5,619	5,562	6,164	7,100
Operating profit	1,051	1,094	1,136	3,228	1,897
OPM %	19.1%	19.5%	20.4%	52.4%	26.7%
Interest	71

Annual P&L

Last 4 years · ₹ Cr · all line items

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Revenue	16,193	16,270	19,656	22,192
Operating profit	551	889	2,797	4,345
OPM %	3.4%	5.5%	14.2%	19.6%
Interest	107	240	279	271

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
LUPINTHIS Lupin Limited	₹2,326.1	+15.8%	1,06,756	23.0	5.43	—	0.32	+13.5%
DIVISLAB Divi's Laboratories Limited	₹6,229	+5.7%	1,66,714	67.2	10.81	16.1%	0.01	+12.3%
APOLLOHOSP Apollo Hospitals Enterprise Limited	₹7,699	+7.8%	1,10,096	61.0	12.11	19.8%	0.84	+17.2%
DRREDDY Dr. Reddy's Laboratories Limited	₹1,235.7	+5.0%	1,02,626	18.2	2.76	16.1%	0.18	+4.4%
CIPLA Cipla Limited	₹1,240.8	-17.9%	99,317	21.9	3.02	13.8%	0.01	0.0%
MAXHEALTH Max Healthcare Institute Limited	₹1,007.65	-6.1%	98,448	69.7	9.85	—	0.33	+30.0%
MANKIND Mankind Pharma Limited	₹2,125	-17.9%	87,619	49.2	5.73	—	0.54	+18.1%
AUROPHARMA Aurobindo Pharma Limited	₹1,386	+15.4%	80,209	23.0	2.29	9.9%	0.22	+9.4%
ALKEM Alkem Laboratories Limited	₹5,582	+11.6%	67,578	28.5	5.06	17.8%	0.17	+2.3%

ASK AXEL

Dig deeper into LUPIN

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for LUPIN — all in one sourced reply.

Ask free in chat

Run these tools on LUPIN

Historical return →

"If I had bought LUPIN in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on LUPIN

Brokerage + charges →

All-in cost for trading LUPIN

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	27.68	32.18	+16.3%
-2q	26.01	32.28	+24.1%
-3q	23.21	26.62	+14.7%
-4q	16.47	16.87	+2.4%

Date	Amount
2025-07-25	₹12.00
2024-07-16	₹8.00
2023-07-14	₹4.00
2022-07-14	₹4.00
2021-07-27	₹6.50
2020-08-03	₹6.00
2019-07-29	₹5.00
2018-07-30	₹5.00
2017-07-24	₹7.50
2016-07-25	₹7.50

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Equity capital	91	91	91	91
Reserves	9,288	9,536	11,183	14,071
Borrowings	4,158	4,542	2,922	5,448
Other liabilities	134	160	189	205
Total liabilities	21,821	22,956	23,997	29,205
Fixed assets	5,490	5,678	5,561	5,614
CWIP	940	1,033	662	465
Investments	47	47	201	70
Other assets	138	198	138	181
Total assets	21,821	22,956	23,997	29,205

Metric	2022-FY	2023-FY	2024-FY	2025-FY
CF Operating	367	1,897	3,648	3,000
CF Investing	1,292	-1,287	-1,712	-4,172
CF Financing	-1,572	-337	-2,184	1,732
Net cash flow	87	273	-248	560
Free cash flow	-538	398	2,719	1,318

Metric	2025-FY	2024-FY	2023-FY	2022-FY
OPM %	19.6%	14.2%	5.5%	3.4%
Net margin %	14.8%	9.7%	2.6%	-9.4%
ROE %	25.8%	18.3%	4.5%	-16.3%
ROCE %	25.4%	19.0%	6.9%	-9.3%
Debt / Equity	0.38	0.26	0.47	0.44
Interest coverage	15.8×	9.7×	4.0×	-11.8×
Revenue growth YoY	+12.9%	+20.8%	+0.5%	—
Profit growth YoY	+71.4%	+345.1%	+128.1%	—

LUPINLupin Ltd

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Quarterly results

Annual P&L

Peer comparison · Healthcare

Ask Axel about LUPIN

Recent news

Dig deeper into LUPIN

Run these tools on LUPIN

Technical snapshot

Earnings history + surprises

Dividends + splits history

Stock scorecard

SWOT analysis

Recent news

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Quarterly results

Annual P&L

Balance sheet

Cash flow statement

Ratios

Peer comparison · Healthcare